m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00661)
Name
8-Methoxy-2-phenyl-3H-quinazolin-4-one
Status
Investigative
Structure
Formula
C15H12N2O2
InChI
1S/C15H12N2O2/c1-19-12-9-5-8-11-13(12)16-14(17-15(11)18)10-6-3-2-4-7-10/h2-9H,1H3,(H,16,17,18)
InChIKey
XMLHWESTKAFTNA-UHFFFAOYSA-N
PubChem CID
135439437
TTD Drug ID
D06NKJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Poly [ADP-ribose] polymerase 1 (PARP1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-phenyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Methoxy-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-phenyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Methoxy-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
References
Ref 1 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 2 Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem. 1998 Dec 17;41(26):5247-56. doi: 10.1021/jm980273t.